Key result
Pre-operative erythropoietin therapy raised haemoglobin by 2-5g% above baseline in 90.3% of patients scheduled for potential blood-losing surgery.
Why the study?
Does pre-operative erythropoietin therapy increase haemoglobin in patients with low haemoglobin scheduled for potential blood losing surgery?
Observational (n=31)
No
Does pre-operative erythropoietin therapy increase haemoglobin in patients with low haemoglobin scheduled for potential blood losing surgery?
Pre-operative administration of erythropoietin, haematinics, and antimalarials is effective in raising haemoglobin levels prior to surgery.
Answers are grounded in this paper and cite their sources.
May support preoperative erythropoietin for haemoglobin optimization; leaves open confirmation in randomized trials.
OBJECTIVE: To determine whether a single weekly low dose of erythropoietin (EPO), haematenics and antimalarials is effective in increasing the pre-operative haemoglobin of patients coming for potential blood losing surgery. DESIGN: A prospective observational study. SETTING: The Korle-bu Teaching Hospital, Accra, Ghana. SUBJECTS: Thirty one patients with low haemoglobin scheduled for potential blood losing surgery. RESULTS: A mean weekly dose of EPO administered of 10,840 +/- 640 IU raised the haemoglobin by 2-5g% above baseline levels in 28 (90.3%) of the patients. Twenty five (81%) of the patients had an uneventful normovolaemic haemodilution during their surgery. CONCLUSION: A single weekly dose of 150 ug/kg of EPO, haematenics, chloroquine (anti-malarial) and a high protein diet is efficacious in raising the pre-operative haemoglobin in Ghanaian patients.
No takes yet. Share an insight, caveat, or question.
Aniteye et al. (2008) conducted an observational in Low haemoglobin scheduled for potential blood losing surgery (n=31). Erythropoietin (EPO), haematenics and antimalarials was evaluated on Increase in pre-operative haemoglobin by 2-5g% above baseline. Pre-operative erythropoietin therapy raised haemoglobin by 2-5g% above baseline in 90.3% of patients scheduled for potential blood-losing surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: